ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 176 filers reported holding ASCENDIS PHARMA A/S in Q4 2020. The put-call ratio across all filers is 1.39 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,638 | -10.6% | 167 | -14.8% | 0.00% | 0.0% |
| Q2 2023 | $17,493 | -41.5% | 196 | -29.7% | 0.00% | -33.3% |
| Q1 2023 | $29,915 | -30.0% | 279 | -20.3% | 0.00% | -40.0% |
| Q4 2022 | $42,746 | +47.4% | 350 | +25.4% | 0.01% | +25.0% |
| Q3 2022 | $29,000 | +81.2% | 279 | +59.4% | 0.00% | +100.0% |
| Q2 2022 | $16,000 | -33.3% | 175 | -14.6% | 0.00% | -33.3% |
| Q1 2022 | $24,000 | -33.3% | 205 | -22.3% | 0.00% | -25.0% |
| Q4 2021 | $36,000 | +5.9% | 264 | +23.9% | 0.00% | -20.0% |
| Q3 2021 | $34,000 | +47.8% | 213 | +23.8% | 0.01% | +66.7% |
| Q2 2021 | $23,000 | +155.6% | 172 | +145.7% | 0.00% | +200.0% |
| Q1 2021 | $9,000 | +28.6% | 70 | +59.1% | 0.00% | 0.0% |
| Q4 2020 | $7,000 | +75.0% | 44 | +63.0% | 0.00% | 0.0% |
| Q3 2020 | $4,000 | 0.0% | 27 | +3.8% | 0.00% | 0.0% |
| Q2 2020 | $4,000 | – | 26 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,909,742 | $911,991,000 | 16.68% |
| Vivo Capital, LLC | 1,797,745 | $277,428,000 | 16.03% |
| Sofinnova Investments, Inc. | 1,109,874 | $171,276,000 | 12.70% |
| Asymmetry Capital Management, L.P. | 81,442 | $12,568,000 | 8.08% |
| Ghost Tree Capital, LLC | 130,000 | $20,062,000 | 5.80% |
| Eversept Partners, LP | 161,004 | $24,846,137 | 5.52% |
| Eventide Asset Management | 1,709,848 | $263,864,000 | 5.16% |
| Avoro Capital Advisors LLC | 1,800,000 | $277,776,000 | 3.95% |
| BERYLSON CAPITAL PARTNERS, LLC | 72,700 | $11,219,000 | 3.93% |
| Spyglass Capital Management LLC | 547,022 | $84,416,000 | 3.90% |